TUSTIN, Calif., March 13, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming CDMO industry conferences. These include KNect365 Life Sciences’ BioProcess International West 2018, being held March 19-22, 2018 in San Francisco, CA, and DCAT Week 2018, being held March 19-22, 2018 in New York, NY.
Details of these activities are as follows:
KNect365 Life Sciences' BioProcess International West:
Avid will host corporate booth #415 showcasing the company’s comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services. Company representatives will provide a virtual tour of Avid’s 40,000 square foot state-of-the-art commercial biomanufacturing suite (Myford facility). The Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process. A wide range of innovative features are incorporated into the facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions. Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing.
DCAT Week:
Avid representatives will also be onsite at DCAT Week, an event hosted by the Drug, Chemical & Associated Technologies Association (DCAT). In addition to participating in related networking events, the company is hosting a table at the DCAT Annual Dinner on Thursday, March 22.
For additional details on these events, please visit: https://lifesciences.knect365.com/bpi-west/ and https://dcatweek.org/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



